[{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Lirum Therapeutics
LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor. It is being investigated in IGF-1R related malignancies and Thyroid eye disease.
Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies and development of lead candidate LX-101, for working capital, and to potentially expand its product candidate pipeline.